Natural History of Untreated 6cm Groin Lymph Node from Metastatic Cutaneous SCC
Without treatment, this patient will almost certainly experience progressive local disease with high likelihood of fungation, ulceration, bleeding, pain, and eventual distant metastatic spread, with death occurring within 1-2 years.
Expected Disease Progression
The natural history of a 6cm metastatic lymph node from cutaneous SCC that declines all treatment follows a predictable and grim trajectory:
Local Complications (Weeks to Months)
- Progressive nodal enlargement with compression of surrounding structures
- Skin breakdown and fungation - the tumor will likely ulcerate through the overlying skin
- Chronic bleeding from the fungating mass, potentially requiring repeated interventions
- Severe pain from nerve compression and tissue invasion
- Lymphedema of the affected leg from lymphatic obstruction
- Secondary infection of the ulcerated tumor with malodorous discharge
- Potential vascular erosion with risk of catastrophic hemorrhage
Systemic Progression (Months)
- Distant metastases will develop in the majority of patients, most commonly to lungs, liver, and bone
- Cachexia and constitutional decline from advanced malignancy
- Death within 1-2 years is the expected outcome
Evidence Supporting This Prognosis
The research data, while focused on treated patients, provides critical context for understanding untreated disease. Even with aggressive multimodal therapy (surgery plus radiotherapy), outcomes for groin metastases from cutaneous SCC are sobering:
- 2-year overall survival of only 50% and 5-year survival of 33% with optimal treatment 1
- Recurrence rates of 26% even after curative-intent surgery and adjuvant radiotherapy 2
- Nodes larger than 6cm have significantly worse local control and higher regional recurrence rates (34% vs 10% for smaller nodes) 3
Without any treatment, survival would be substantially worse than these already poor outcomes.
Why Radiotherapy Matters Here
The evidence demonstrates that radiotherapy provides meaningful benefit even for large nodes:
- RT achieves 81% objective response rate (52% complete response) for lymph node metastases 4
- Median local progression-free survival of 40 months with RT for nodes <40mm 4
- RT contributes to better overall survival (HR 0.47) compared to no adjuvant therapy 5
- For nodes ≥40mm (like this 6cm node), local control drops dramatically to median 6.6 months even with RT 4
This means that even with palliative RT, a 6cm node has limited local control - without it, progression is essentially guaranteed and rapid.
Quality of Life Considerations
The guideline appropriately emphasizes that "for patients with advanced disease, it is also appropriate to provide or refer to best supportive and palliative care to optimize symptom management and maximize quality of life" 6.
Declining radiotherapy does not mean declining all care. The patient should be strongly counseled about:
- Palliative care referral for aggressive symptom management
- Wound care for inevitable fungation and ulceration
- Pain management including opioids and neuropathic agents
- Hemostasis planning for bleeding episodes
- Goals of care discussions and advance care planning
Clinical Pitfalls
The most common error is underestimating the morbidity of untreated bulky nodal disease. A 6cm groin node will not remain stable - it represents aggressive biology that will cause significant suffering through local progression alone, independent of distant metastases.
The patient may not fully appreciate what "declining treatment" means in practical terms - they need explicit counseling about fungation, bleeding, pain, and odor that will develop, not just abstract discussions of survival statistics.